Cargando…

Waning Immunity after the BNT162b2 Vaccine in Israel

BACKGROUND: In December 2020, Israel began a mass vaccination campaign against coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to a sharp curtailing of the outbreak. After a period with almost no cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldberg, Yair, Mandel, Micha, Bar-On, Yinon M., Bodenheimer, Omri, Freedman, Laurence, Haas, Eric J., Milo, Ron, Alroy-Preis, Sharon, Ash, Nachman, Huppert, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/ https://www.ncbi.nlm.nih.gov/pubmed/34706170 http://dx.doi.org/10.1056/NEJMoa2114228

Ejemplares similares

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study
por: Amir, Ofra, et al.
Publicado: (2023)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
por: Goldberg, Yair, et al.
Publicado: (2022)

Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine
por: Amir, Ofra, et al.
Publicado: (2022)

Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster
por: Amir, Ofra, et al.
Publicado: (2023)

BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals
por: Mor, Orna, et al.
Publicado: (2022)

Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Reporting of Allergic Reactions During Pfizer-BioNTech BNTT162B2 Vaccination in Israel
por: Anis, Emilia, et al.
Publicado: (2022)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
por: Lustig, Yaniv, et al.
Publicado: (2021)

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
por: Suah, Jing Lian, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
por: Haas, Eric J, et al.
Publicado: (2022)

Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021
por: Muhsen, Khitam, et al.
Publicado: (2022)

Civil-military cooperation to contain COVID-19 epidemic in Israel- Lesson learned: Zohar Mor
por: Mor, Z, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
por: Glatman-Freedman, Aharona, et al.
Publicado: (2022)

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
por: Hatzakis, Angelos, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel
por: Glatman-Freedman, Aharona, et al.
Publicado: (2023)

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
por: Haas, Eric J, et al.
Publicado: (2021)

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals
por: Szekanecz, Zoltán, et al.
Publicado: (2023)

Waning Humoral Response 6 Month after Double Vaccination with the mRNA-BNT162b2 Vaccine in Hemodialysis Patients
por: Balčiuvienė, Vilma, et al.
Publicado: (2023)

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
por: Glatman-Freedman, Aharona, et al.
Publicado: (2021)

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study
por: Singer, Shepherd R., et al.
Publicado: (2021)

The Israeli Experience with the “Green Pass” Policy Highlights Issues to Be Considered by Policymakers in Other Countries
por: Waitzberg, Ruth, et al.
Publicado: (2021)

Protective Effects of BNT162b2 Vaccination on Aerobic Capacity Following Mild to Moderate SARS-CoV-2 Infection: A Cross-Sectional Study Israel
por: Blumberg, Yair, et al.
Publicado: (2022)

The global mass and average rate of rubisco
por: Bar-On, Yinon M., et al.
Publicado: (2019)

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
por: Prunas, Ottavia, et al.
Publicado: (2021)

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
por: Prunas, Ottavia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vbn7rldqv9pa8h25fsi1tic0og